Core Insights - Pasithea Therapeutics Corp. has appointed Dr. Rebecca Brown to its Scientific Advisory Board to aid in the development of PAS-004, a next-generation macrocyclic MEK inhibitor targeting neurofibromatosis type 1 (NF1) and other indications [1][4] Company Overview - Pasithea is a clinical-stage biotechnology company focused on innovative treatments for central nervous system disorders and RASopathies, including NF1, solid tumors, and amyotrophic lateral sclerosis (ALS) [8] Dr. Rebecca Brown's Role - Dr. Brown is the Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and brings extensive experience in NF1 research, having participated in numerous studies related to cutaneous and plexiform neurofibromas [2][3] - Her expertise will provide valuable clinical insights as the company prepares to initiate its Phase 1/2a clinical trial for PAS-004 [4] PAS-004 Development - PAS-004 is designed as a small molecule allosteric inhibitor of MEK 1/2, targeting the MAPK signaling pathway, which is crucial for tumor growth and other cellular functions [6] - The drug aims to overcome limitations of existing MEK inhibitors by offering improved pharmacokinetic and safety profiles, a longer half-life, and potentially better therapeutic index [6][7] - PAS-004 has received orphan-drug designation from the FDA for NF1, which may grant seven years of marketing exclusivity upon NDA approval [7]
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board